Prevalence of Contrast Nephropathy in Type 2 Diabetes Patients With Microalbuminuria
Phase of Trial: Phase IV
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Linagliptin (Primary) ; CD26 antigen inhibitors
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Acronyms VCG4
- 06 Sep 2019 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 31 Jul 2018 Planned End Date changed from 30 Aug 2018 to 30 Nov 2018.